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thousands of named genes of known function as wellA.L. Shaffer, Andreas Rosenwald, Elaine M. Hurt,
Jena M. Giltnane, Lloyd T. Lam, Oxana K. Pickeral, as genes of unknown function derived from normal and
malignantly transformed lymphocyte cDNA libraries.and Louis M. Staudt1
Metabolism Branch The mRNA expression from two samples is compared
on a single microarray by converting each RNA into aNational Cancer Institute
National Institutes of Health cDNA probe that incorporates a different fluorochrome
(Cy5 or Cy3). Following hybridization of these probes to9000 Rockville Pike
Building 10, Room 4N114 a single array, the array is washed and scanned to reveal
the hybridization of the probes to each spot on the array.Bethesda, Maryland 20892
These Cy5 and Cy3 fluorescence measurements are
converted into ratios of relative gene expression (Cy5/
Cy3) that accurately reflect the true difference in mRNASummary
levels between samples (Schena et al., 1995, 1996; Shaf-
fer et al., 2000; Taniguchi et al., 2001).A compendium of global gene expression measure-
ments from DNA microarray analysis of immune cells A single microarray provides thousands of individual
gene expression measurements and, in a short periodidentifies gene expression signatures defining various
lineages, differentiation stages, and signaling pathways. of time, a scientist can perform a series of microarray
experiments that populate a database with many mil-Germinal center (GC) B cells represent a discrete stage
of differentiation with a unique gene expression signa- lions of measurements. Though there are many ways
to parse these enormous gene expression data setsture. This includes genes involved in proliferation, as
evidenced by high expression of G2/M phase regula- (Bassett et al., 1999; Sherlock, 2000), we use hierarchical
clustering, based on Pearson correlation relationships,tors and low expression of ribosomal and metabolic
genes that are transcriptional targets of c-myc. GC B as the primary tool for data mining (Eisen et al., 1998).
Clustering can group genes with similar expression pat-cells also lack expression of the NF-B signature
genes, which may favor apoptosis. Finally, the tran- terns across all samples, group samples with similar
gene expression patterns, or both. This process definesscriptional repression signature of BCL-6 reveals how
this factor can prevent terminal differentiation of B gene expression signatures composed of genes that
are coordinately expressed in samples related by somecells and cause B cell lymphomas.
identifiable criterion such as cell type, differentiation
state, or signaling response.Introduction
The light at the end of the reductionist tunnel has turned Figure 1 presents a compendium of gene expression
data assembled from 986 Lymphochip experiments (col-out to be the headlight of a locomotive called genomics.
Now that complete genome sequences are known for umns) and representing approximately 2000 genes mea-
sured by 3418 array elements (rows). Data are displayedmany organisms, including ourselves, we are faced with
the daunting task of resynthesis. How can we make using a color scale to indicate the level of gene expres-
sion relative to an appropriate control sample; red de-functional sense of a genome’s worth of nucleotide se-
quence? We need a map. A powerful cartographic tool notes higher and green denotes lower expression. Hori-
zontal colored bars indicate the cell type and/or conditionsfor exploring the genome is gene expression profiling, a
technology that can provide an overview of the genome tested, whereas vertical black bars delimit gene expres-
sion signatures as described below.interacting with its environment. Taking this genomic
view of the immune system, one sees a wonderfully
integrated set of gene expression programs that allow Gene Expression Signatures of Lineage
immune cells to respond to internal developmental cues and Developmental Stage
and external antigenic challenges. Although there are Immunologists have used many criteria to define devel-
many ways to monitor global gene expression, we will opmental stages as cells progress from immature pre-
focus on the insights gained using cDNA microarrays cursors to terminally differentiated effectors, including
(Staudt and Brown, 2000). DNA rearrangement status, surface marker expression,
The application and analysis of cDNA microarrays and protein secretion. Microarrays provide a new, com-
have been reviewed previously (Alizadeh and Staudt, prehensive way to define these stages by their charac-
2000; Staudt, 2001). In brief, a substrate, typically a teristic gene expression signatures.
glass slide or silicon wafer, is arrayed with cDNAs or Signatures defining the B and T lymphocyte lineages
oligonucleotides complementary to transcripts from are readily identified in this gene expression map (Figure
several thousand genes. We have developed a microar- 1). The T cell signature contains components of the
ray referred to as the Lymphochip which holds more T cell receptor (TCR, TCR, CD3, CD3), signaling
than 10,000 individual human cDNAs on a single slide proteins (LAT, TRIM, SAP), and surface markers (CD5,
(Alizadeh et al., 1999, 2000). The Lymphochip gene set is CD2). An extensive B cell signature is defined by compo-
enriched for genes expressed in lymphocytes, including nents associated with the B cell receptor ( heavy chain,
CD79A, CD79B, syk, btk, lyn), as well as other cell sur-
face receptors (CD20, CD19, CD22, CD27, CD40, CD45,1Correspondence: lstaudt@mail.nih.gov
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Figure 1. Lymphochip Clustering Analysis Defined Gene Expression Signatures
Gene expression measurements are shown from 986 microarray experiments investigating normal immune cells and disease states (see key
at right). 3814 common array elements (approximately 2000 unique genes) were analyzed by hierarchical clustering. Data filters based on
spot quality and signal intensity were used to capture the most reliable data. Spots not meeting these criteria were excluded from analysis
and appear gray. Relative gene expression levels (ratios) are indicated by the color bar in the lower right. Gene expression signatures are
described in detail in the text.
and CD72) and transcription factors (PAX5, OCT-2, IL-1, LARC, MCP-1, GRO2). Many genes involved in the
organization of secondary lymphoid organs are found inSpi-B) important in B cell development.
Microarray analysis also identifies the distinct genetic this signature: chemokines (BLC, APRIL), matrix compo-
nents (fibronectin, collagen), and matrix regulators (ma-programs characterizing different developmental stages
within a lineage. Two stages of B cell differentiation, trix metalloproteases [MMPs], tissue inhibitors of metal-
loproteases [TIMPs]). Whether this signature representsplasma cells and germinal center (GC) B cells, have their
own signatures (Figure 1). The plasma cell signature is a normal lymph node signature or reflects the reaction
of the nonlymphoid lineages to the B cell tumor remainsdefined by two gene clusters that include two transcrip-
tional regulators of plasmacytic differentiation, blimp-1 an interesting area to be explored.
and XBP-1, as well as the adhesion molecule synde-
can-1 (Messika et al., 1998; Reimold et al., 2001; Turner Gene Expression Signatures of Cellular Physiology
The global view of gene expression provided by microar-et al., 1994). Microarray analysis also defines a GC B
cell-specific signature which will be discussed in detail rays makes it clear that certain cellular processes, like
proliferation, are coordinated at the level of gene expres-below (Figures 1 and 4, see also Alizadeh et al., 2000;
Ma and Staudt, 2001). sion. By far the largest set of coherently regulated genes
in Figure 1 are those found in the proliferation signatureThere is also a prominent signature representing sev-
eral nonlymphoid lineages that arises from the analysis (Alizadeh et al., 2000; Perou et al., 1999). This signature
includes genes involved in cell cycle regulation (cyclins,of lymph node biopsies taken from patients with diffuse
large B cell lymphoma (DLBCL) (Figure 1 and Alizadeh cyclin-dependent kinases, cell cycle checkpoint pro-
teins), DNA synthesis (nucleotide metabolism enzymes,et al., 2000). This includes several macrophage (CD18,
CD64) and NK cell (NK4, CD49, NKG5) markers in addi- polymerases), and protein translation (ribosomal pro-
teins, translation elongation factors). Within this largetion to genes expressed in activated monocytes (IL-8,
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proliferation signature, a fascinating substructure is ob- ure 1: the interferon pathway, the immediate early path-
way, and the NF-B pathway.served in which genes are grouped according to their
A two-part signature involves interferon responsivefunction in the cell cycle, as discussed in detail below
genes. The “split” nature of this gene expression signa-(Figure 4B).
ture relates to the different biological functions of theseAnother functional signature comprises a set of genes
interferon-inducible genes, which have recently beeninvolved in actin regulation. At the core of this signature
compiled in a searchable database (de Veer et al., 2001).are  and  actin, which are involved in cell motility,
Interferons signal primarily through the transcription fac-cytokinesis, and endocytosis. Two other genes in this
tors STAT-1, STAT-2, and the IRFs (reviewed in Chat-signature are also involved in actin polymerization based
terjee-Kishore et al., 2000; Stark, 1997; Stark et al., 1998).on their interaction with the Wiskott-Aldrich Syndrome
However, in STAT-1-deficient cells, STAT-1-indepen-protein (WASP): G25K, the human homolog of cdc24 and
dent interferon signaling has been observed, indicatinga ras superfamily GTPase, and WIP (WASP-interacting
that interferon signals are also processed by alternateprotein). The remaining actin signature proteins bind
pathways (Meraz et al., 1996). STAT-1 itself can also beactin directly. ARP 2/3 induces actin polymerization,
activated by many noninterferon stimuli (Dimberg et al.,whereas GAS2 associates with actin fibers mediating
2000; Seebach et al., 2001; Wong et al., 2001), sug-cell cycle arrest. Thymosin 4 controls actin dynamics
gesting that although the interferon-inducible genesby sequestering actin.
cluster together, they may do so independent of theCoordinate expression of actin regulatory genes may
action of interferons themselves. The first interferon sig-orchestrate the reorganization of the actin cytoskeleton,
nature (IFN-1, Figure 1) contains genes involved in pro-an essential step in lymphocyte activation (reviewed in
tein catabolism. Three components of the proteosomeBauch et al., 2000; Dustin and Cooper, 2000; Penninger
(macropain, LMP2, and MECL-1) are grouped with aand Crabtree, 1999). Although it was observed nearly
component of the ubiquitin-conjugating system, E2L6.30 years ago that crosslinking-induced “capping” of an-
Components of the proteosome pathway have been ob-tigen receptors on B cells was dependent on actin poly-
served to be coordinately transcribed in yeast (Eisen etmerization, it was not until T cell activation was studied
al., 1998), and ubiquitin-conjugating enzymes have beenthat the role of actin was truly appreciated. Actin plays
shown to be upregulated at the protein level in T cellstwo roles in T cell activation: formation of the synapse
treated with interferon- (Nyman et al., 2000). In addi-between the T cell and the antigen-presenting cell (APC)
tion, MHC class I and 2 microglobulin genes appearand organization of intracellular signaling components.
in this signature, indicating that a program dedicated toResting T cells have actin structures that sequester anti-
tagging, degrading, and presenting intracellular anti-gen, chemokine, and adhesion receptors in inaccessible
gens is coordinately controlled. This signature also con-regions of the plasma membrane. Upon activation, reor-
tains the interferon-responsive transcription factors,ganization of actin microfilaments leads to the formation
STAT-1 and IRF-1, that crossregulate one another. Theof SMACs (supramolecular activation clusters) between
second interferon signature (IFN-2) contains genes thatthe T cell and the APC, thereby promoting sustained
promote resistance to viral infection. Present in this sig-interactions between the T cell receptor (TCR) and MHC
nature are the Mx genes, GTPases that mediate resis-molecules and initiating intracellular signals. These TCR
tance to influenza. The IFN-2 signature also includessignals in turn activate Cdc42Hs, which causes WASP
25-oligoadenylate synthase whose products activateto stimulate the Arp2/3 complex, leading to remodeling
RNase L, an enzyme that can degrade viral RNA. Inter-of the actin cytoskeleton. Two lines of evidence point
estingly, HEM45, a functional relative of RNase L, is alsoto the absolute requirement for actin cytoskeleton reor-
present in this signature. Another antiviral gene in thisganization in promoting and sustaining T cell activation.
signature is interferon-inducible double stranded RNA-First, drugs that disrupt actin polymerization, like cyto-
dependent kinase, an enzyme that terminates transla-
chalasin, immediately curtail T cell activation. Second,
tion in infected cells by phosphorylating elongation fac-
T cells from patients with Wiskott-Aldrich syndrome, an
tors. The IFN-2 signature reflects a coordinated effort
X-linked immunodeficiency characterized by a defi- by cells to reclaim control of their intracellular machinery
ciency in WASP, fail to properly proliferate or secrete upon viral infection.
IL-2 upon TCR engagement (Snapper and Rosen, 1999). When the cellular environment acutely changes, either
The fact that actin and actin regulatory genes are coordi- beneficially as in the presence of growth factors, or
nately regulated was not appreciated prior to microarray stressfully due to heat shock or radiation, cells express
analysis and underscores the importance of the actin a characteristic set of genes known as immediate-early
microfilament system in lymphocyte activation. genes (IEGs). The importance of these rapidly activated
genes is emphasized by the fact that multiple growth
Gene Expression Analysis of Signaling Pathways factors lead to the upregulation of the same stereotypi-
As immune cells progress through development and cal set of IEGs and that distinct signaling pathways
respond to antigenic challenge, they trigger signaling initiated from the same receptor independently cause
pathways that alter the activity of transcription factors, the upregulation of these genes (Fambrough et al.,
changing their gene expression profiles. Since these 1999). The genes involved in the immediate-early re-
same signaling modules are engaged in diverse re- sponse form a distinct cluster in Figure 1. Among these
sponses and cell types, the downstream target genes rapidly inducible genes are the prototypical IEGs c-fos
of these signaling events are grouped together in gene and c-jun, two components of the transcription factor
expression maps. Three signaling pathways are repre- AP-1 (reviewed in Wagner, 2001) that is involved in acti-
vating gene expression from a host of immunologicallysented by prominent gene expression signatures in Fig-
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important genes involved in growth and differentiation
(Foletta et al., 1998; Shaulian and Karin, 2001). Several
other genes of diverse function make up this signature:
HSP70, named for its role in heat shock responses and
involved in the folding of proteins; MKP-1, a phospha-
tase that dephosphorylates MAP kinases; CPBP, a tran-
scription factor that enhances initiation from TATA-less
promoters; and TTP, which binds certain mRNAs and
promotes their degradation. The functional logic that
knits together these diverse IEGs will take more experi-
mentation to fully understand.
Stimulation of lymphocytes through their antigen re-
ceptors initiates cell cycle entry and changes gene ex-
pression, a response generically referred to as “activa-
tion.” Likewise, cells of the innate immune system
responding to invading pathogens become activated
and alter their gene expression profiles. Several distinct
activation signatures are present in Figure 1, the most
prominent of which features targets of the transcription
factor NF-B (Figure 2). NF-B is shorthand for a family
of related proteins which dimerize to form transactivat-
ing complexes (Baldwin, 1996; Ghosh et al., 1998; Karin
and Ben-Neriah, 2000; Pahl, 1999; Siebenlist et al.,
1994). NF-B dimers are sequestered in the cytoplasm
by interaction with inhibitory proteins (the IBs). Various
stimuli activate kinase signaling cascades that result in
the phosphorylation and degradation of IB, thereby
releasing NF-B to translocate to the nucleus where it
activates transcription of target genes. Several studies
have emphasized the essential role of this transcription
factor family in regulating genes at critical points in lym-
phocyte development and activation (Gugasyan et al.,
2000). Many NF-B targets are antiapoptotic (A1, BCL-
XL, BCL-2, c-IAP2), which may explain the importance
of the NF-B pathway in oncogenesis and resistance
of tumors to chemotherapy (Baldwin, 2001; Rayet and
Gelinas, 1999). Other genes in this signature are proin-
flammatory cytokines and chemokines (MIPs, IL-8, etc.)
that are acutely upregulated during an immune re-
sponse. The remaining genes included components of
the NF-B pathway itself: RelB, NFB2, IB, and IB.
Because expression of any given gene depends upon
integrating the input from multiple pathways, it is not
surprising that some NF-B target genes appear in other
parts of the cluster analysis (Figures 1 and 2). An activa-
tion signature representing genes induced during B cell,
T cell, and monocyte activation includes the NF-B tar-
Figure 2. Gene Expression Signatures of Immune Cell Activationget Bcl-XL, and an activation signature representing
Each signature represents a group of genes that cluster togethergenes induced in lymphocytes includes the NF-B tar-
based on similarity in gene expression patterns across the entiregets BCL-2, IRF-4, and cyclin D2. A final activation sig-
set of microarray experiments shown in Figure 1. The behavior ofnature is comprised of a few genes expressed specifi-
these genes is shown only for primary T cells activated by PMAcally in activated T cells, notably the cytokines IL-2 and
plus ionomycin or Con A plus PHA for 3 hr, primary monocytes
IL-4, whose transcription relies on the activation of both activated with LPS for 2 and 8 hr, and purified peripheral blood B
NF-B and NFAT. Thus, gene expression signature anal- cells activated with anti-IgM, CD40L, and IL-4 over a time course
ysis alone may not provide a complete picture of the at 0, 1, 3, 6, and 24 hr. Red indicates high expression; green repre-
sents low expression; and gray indicates that the gene was notgenes that are targeted by a particular signaling path-
expressed at a level meeting confidence criteria.way, and the next sections detail other approaches that
are additionally helpful in delineating the gene expres-
perturb the pathway discretely and measure how thesion consequences of intracellular signaling events.
system responds to the perturbation. We have many
tools at our disposal: genetics (via the use of transgenicGene Expression Physiology
animals or the study of patients with disease), pharma-of Immune Responsiveness
cology, and molecular biology (transfection or transduc-To reveal the downstream effects of a signaling pathway
by gene expression analysis, we would ideally like to tion of activators or inhibitors of a pathway).
Review
379
Figure 3. Gene Expression Physiology of Immune Responses
(A) Calcium-dependent T cell signaling. Microarray analysis of normal versus calcium entry-deficient (SCID) T cells is shown. T cells of normal
controls and SCID patients were left unstimulated or stimulated with PMA and ionomycin (P/I) for 3 hr. In addition, some control T cells were
preincubated with cyclosporin A (CsA) for 30 min prior to stimulation. Genes upregulated relative to the unstimulated samples appear red,
and downregulated genes appear green. See text and Feske et al. (2001) for details.
(B) Genomic-scale analysis of mRNA stability: differential half-lives of functional classes of mRNAs. PBMC were stimulated with PMA and
ionomycin (P/I) for the indicated times to identify those transcripts with rapid induction kinetics. Genes induced by P/I appear red, and genes
repressed appear green. To determine the half-lives of these transcripts, cells were stimulated with P/I for 3 hr and then treated with the
global transcriptional inhibitor, flavopiridol (flavo), and harvested at the indicated times. Shades of green represent the extent of decrease in
mRNA abundance relative to the control sample not treated with flavopiridol. See Lam et al. (2001) for details. The bar graph shows the
percentage of inducible and noninducible genes within each half-life category.
The Role of Calcium Signaling used to assess whether calcium-regulated genes de-
pended upon the action of the phosphatase calcineurin.in Lymphocyte Activation
In a study of T cell receptor signaling, genetics was used Most calcium-regulated genes were dependent on cal-
cineurin signaling, though a smaller number were lessto elucidate the role of calcium signals in regulating
gene expression (Feske et al., 2001). A rare family of se- affected by CsA than by the SCID defect (e.g., MIP-1
and PBEF, Figure 3A). A single gene, TNF-, was uniquevere combined immunodeficiency (SCID) patients was
found to have an impaired NFAT activation. NFAT tran- in its behavior, as it was more strongly induced in SCID
patient T cells than in normal T cells treated with CsA. In-scription factors turn on many immunologically impor-
tant genes, especially during T cell activation (Crabtree, terestingly, the downregulation of genes by calcium sig-
naling was also dependent on calcineurin. Calcineurin1999; Rao et al., 1997). In a first set of experiments, nor-
mal and SCID T cells were compared, either unstimu- dephosphorylates and activates NFAT, but it could con-
ceivably affect other targets resulting in repression oflated or treated with PMA and ionomycin. Many genes
induced in normal T cells failed to be induced in SCID genes. This example illustrates how the combination of
genetics and pharmacological inhibitors can be usefulpatient T cells. Unexpectedly, microarray analysis re-
vealed a set of genes whose mRNA levels were strongly in dissecting clinically relevant signaling pathways.
Similar approaches have been taken in the study ofdownregulated by calcium signaling in normal T cells
but were not as affected in SCID patient T cells (Figure B cell signaling (Glynne et al., 2000). Anergy is a form
of tolerance in which signals through the B cell receptor3A). Treatment of T cells with cyclosporin A (CsA) was
Immunity
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are altered, thereby preventing activation upon antigen receptors. If one considers the roles of each of these
proteins during an immune response, the logic of thisstimulation. Using a well-defined transgenic system, the
HEL-Ig:HEL-transgenic mouse, the gene expression sig- regulation becomes clear. Cytokines are powerful in-
ducers of immune responses and regulators of effectornature of activated and anergic B cells was compared.
Anergic B cells showed a distinct gene expression sig- functions. To curtail potential bystander effects of cyto-
kines, cells may limit the duration of cytokine productionnature marked by their failure to upregulate genes pro-
moting cell cycle entry and preventing apoptosis, while by rapidly degrading cytokine mRNAs. Many cells, how-
ever, are poised to respond to cytokines, hence thecontinuing to express genes that block activation. This
study also examined whether the immunosuppresive greater stability of mRNAs for cytokine receptors. Che-
mokines, on the other hand, guide cells to sites of anti-drug FK506, which interrupts signaling via the calcium/
calcineurin pathway, has a gene expression effect akin genic challenge, a process that may last for several
days. Cells may therefore need to synthesize chemo-to anergy. In fact, FK506 failed to mimic functional anergy
since it blocked only a fraction of activation-induced kines for extended periods of time, and this is facilitated
by the relative stability of chemokine mRNAs. Once cellsgenes and interfered with the induction of anergy-spe-
cific genes. New immunosuppressant agents that mimic have reached the appropriate site, rapid downregulation
of certain chemokine receptors, promoted by rapidmore closely the gene expression profile of anergy will
be of greater clinical utility (Glynne et al., 2000). mRNA degradation, may allow the cells either to remain
at the site or migrate in response to other chemoattrac-
tants.mRNA Stability and the Control of Immune Responses
The regulation of mRNA stability is a less well-studied
aspect of gene regulation that is as important as tran- The Germinal Center B Cell from Many Gene
Expression Perspectivesscriptional initiation in determining steady-state mRNA
levels. Microarrays were used to assess mRNA stability The multiple experimental and analytical approaches
to gene expression profiling presented thus far can beon a genomic scale by studying cells treated with global
inhibitors of transcription initiation (Lam et al., 2001). An fruitfully combined to understand the biology of a com-
plex immune reaction. To gain insights into the biology ofunexpected relationship between the mRNA half-life of
a given gene and the function of its encoded protein was the germinal center (GC) reaction, the gene expression
profiles of GC B cells were analyzed using gene expres-uncovered. Prior to this analysis, there was no reason to
assume a priori that genes related by function would sion signatures that define B cell developmental stages,
cell cycle dynamics, signaling pathways, and transcrip-also be related in terms of mRNA stability. For example,
genes involved in M phase of the cell cycle (e.g., pLK, tion factor targets (Figure 4).
GC B cells represent a unique stage of differentiationCHK1) had transcripts with short half-lives. Since M
phase is typically the shortest phase of the cell cycle, that arises when B cells encounter antigen in secondary
lymphoid tissues (Figure 5). With help from T cells andit is not surprising that mRNAs encoding proteins in-
volved in this cell cycle step would be rapidly turned dendritic cells, B cells become activated and can differ-
entiate into short-lived plasmablasts and plasma cells.over. Similarly, the class of genes encoding antiapo-
ptotic factors (A20, MCL-1, c-IAP) was relatively en- Alternatively, they may participate in the creation of the
complex microenvironment called the germinal center.riched in labile mRNAs, suggesting that the prevention
of programmed cell death is a dynamic process that In the GC, rapid proliferation is coupled to a process of
antigen receptor mutation and selection called affinitymust be capable of rapid modulation.
The most striking relationship uncovered was that maturation, resulting in the production of B cells with
higher affinity antigen receptors than the cells thattranscriptionally inducible genes are much more likely
to produce labile mRNAs than are noninducible genes founded the GC. After exiting the GC, GC B cells differ-
entiate into either memory B cells or plasma cells(Lam et al., 2001). This relationship was found by study-
ing the mRNA half-lives of genes that were induced (McHeyzer-Williams et al., 2001).
To gain insight into the biology of GC B cells, weduring activation of peripheral blood mononuclear cells
(PBMC) with PMA and ionomycin (Figure 3B). A majority identified genes characteristic of this developmental
stage in two separate ways (Figure 4A). The upper partof inducible transcripts have very short half-lives (	2
hr), whereas transcripts whose levels were unaffected of this panel shows those genes that comprise the GC
B cell signature as defined by the gene expression mapby activation tend to be long lived (
6 hr). A clear regula-
tory logic emerges from this observation. Presumably, in Figure 1. We observed, however, that certain genes
believed to be GC specific, like AID, were missing fromthe inducible genes require both rapid up- and downmo-
dulation of their mRNA levels in order to, on one hand, this signature. Therefore, these genes were extracted
mathematically from the array data based on higherrespond acutely to changes in cellular physiology but,
on the other hand, terminate this response rapidly. This average expression in GC B cells as compared to quies-
cent B cells, and these genes are shown in the lowerresponse profile can only be achieved by transcriptional
regulation coupled with a short mRNA half-life. panel. These genes most likely integrate signals from
multiple pathways, which causes them to migrate toThe stability of mRNAs encoding cytokines, chemo-
kines, and their respective receptors showed an inter- distinct clusters in large gene expression maps.
The gene expression profile of GC B cells includesesting dichotomy (Figure 3B). Cytokine transcripts were
found to have substantially shorter half-lives than those many previously identified differentiation markers such
as CD10, CD38, BCL-6, A-myb, and the human homologfor chemokines. Conversely, mRNAs for cytokine recep-
tors were quite stable compared to those for chemokine of the mouse GC-specific gene M17. In addition to those
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Figure 4. Multiple Microarray Perspectives on GC B Cell Biology
(A) GC B cell developmental signature. Gene expression data from primary B cells (Ma and Staudt, 2001), T cells, and monocytes, with or
without activation as described in Figure 2, are presented. The GC B cell signature derived from Figure 1 is shown in the upper portion of
the panel. Genes more highly expressed by GC B cells but not part of this signature were extracted mathematically and are displayed in the
lower panel (see text).
(B) Expression of proliferation signature genes in GC B cells. The same samples as shown in (A) are displayed with the addition of a series
of B cell lines (OCI-Ly3 through U266), as well as a T cell line (Jurkat) and a monocyte cell line (U937). Subclusters of genes involved in various
functions (mitosis, protein synthesis, and glycolysis) are shown.
(C) Expression of NF-B target genes in GC B cells. Samples are the same as in (A).
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named genes illustrated in Figure 4A, the Lymphochip to undergo programmed cell death. In keeping with this
notion, one of the GC B cell signature genes is BIK, amicroarrays contain a host of novel genes that are germi-
nal center-restricted in their expression. It is important member of the BCL-2 family that promotes apoptosis.
Finally, we have begun to study GC B cell physiologyto emphasize that the expression of these GC B cell
signature genes is maintained in lymphoma cell lines by manipulating individual regulatory factors in these
cells and monitoring the resultant changes in gene ex-derived from GC B cells (Alizadeh et al., 2000); thus, the
GC B cell program can be maintained in the absence pression. In an initial application of this approach, we
identified the target genes of the transcriptional repres-of interacting T cells or follicular dendritic cells. This
observation demonstrates that the GC B cell represents sor BCL-6 (Shaffer et al., 2000). BCL-6 is normally ex-
pressed in GC B cells, and its misexpression is associ-a discrete stage of B cell differentiation with a stable
gene expression program and not simply a particular ated with many B cell non-Hodgkin’s lymphomas,
DLBCL in particular. To elucidate the role of BCL-6 inmode of B cell activation characterized by a transient
change in gene expression. normal B cells, BCL-6 knockout mice were generated
(Dent et al., 1997; Fukuda et al., 1997; Ye et al., 1997).GC B cells divide every 6 hr, placing them among the
most rapidly proliferating cells in the body. To under- In keeping with its expression pattern, ablation of BCL-6
resulted in the complete inability to form germinal cen-stand the highly proliferative nature of GC B cells, we
examined the expression of the proliferation signature ters, and this defect was autonomous to the B cell
lineage.genes in GC B cells (Figure 4B). Within the overall struc-
ture of the large proliferation signature, a remarkable To identify BCL-6 target genes, BCL-6 was introduced
into B cell lines that lack expression of this factor or,substructure was discerned that groups genes having
distinct proliferation functions together. One subcluster alternatively, a dominant-negative form of BCL-6 was
introduced into GC B cell-derived cell lines expressingof genes encodes proteins that participate in the G2/M
phase of the cell cycle. These genes include the cyclin/ the endogenous BCL-6 gene. Microarray analysis of
these manipulated cells revealed that BCL-6 repressescdk pair cyclin B1/CDC2, which drives cells through
G2/M phase, and pLK, which regulates cyclin B1 subcel- a discrete set of genes involved in B cell activation,
inflammation, and terminal differentiation (Figures 5Alular localization. Also found are genes encoding the
centrosome proteins CENP-E and CENP-F and aurora- and 5B). BCL-6 targets include a set of genes that are
induced by signaling through the B cell antigen receptorlike kinase that help organize the mitotic spindle and
genes encoding the mitotic checkpoint proteins BUB1, (CD44, CD69, EBI2, cyclin D2, MIP-1). These target
genes are normally induced in activated B cells prior toMad2, and survivin. Compared to other primary B cells,
GC B cells highly expressed these G2/M phase genes, plasmacytic differentiation, and thus BCL-6 may pro-
mote GC differentiation by blocking the alternative cellreflecting the higher proportion of GC B cells at this
stage of the cell cycle. fate, namely local plasmacytic differentiation in the peri-
arteriolar lymphoid sheath (Figure 5B). Perhaps the mostSurprisingly, two other clusters of genes in the prolif-
eration signature, encoding proteins involved in transla- interesting target of BCL-6 repression is another tran-
scriptional repressor, blimp-1 (Shaffer et al., 2000), thattion and energy metabolism, were downregulated in GC
promotes plasma cell differentiation. By repressingB cells. The first cluster is composed almost entirely of
blimp-1, BCL-6 blocks terminal differentiation of GC Bribosomal subunit genes, and the second is involved in
cells, a notion that was directly validated by the demon-energy production via the glycolytic pathway. Both sets
stration that B cells expressing dominant-negative BCL-of genes contain known targets of the transcription fac-
6 displayed features of plasmacytic differentiation. Intor c-myc (Guo et al., 2000; Schuhmacher et al., 2001),
support of this finding, BCL-6 was shown to block plas-and GC cells have a markedly lower level of c-myc mRNA
macytic differentiation of mouse B cells (Reljic et al.,than mitogenically activated blood B cells (Figure 4B).
2000). BCL-6 may also play a role in the rapid cell cycleFurthermore, one of the GC B cell signature genes is a
progression of GC B cells by repressing the cdk inhibitorhomolog of the mouse Mad3 gene that dimerizes with
p27kip1 (Shaffer et al., 2000).c-myc and opposes its function as a transcriptional acti-
These findings suggest a credible mechanism byvator. Taken together, this analysis of the proliferation
which BCL-6 causes lymphomas (Shaffer et al., 2000).signature genes revealed that GC B cells favor cell prolif-
BCL-6 translocations remove the normal regulatory ele-eration at the expense of cell growth, a previously unap-
ments in the BCL-6 promoter, thus preventing the tran-preciated aspect of GC B cell physiology.
scriptional silencing of this gene that normally occursAnother perspective on GC B cell physiology came
during plasmacytic differentiation. A GC B cell with afrom an analysis of NF-B target genes in these cells. In
BCL-6 translocation would therefore be trapped at thisaddition to the NF-B signature genes that we described
stage of differentiation due to repression of blimp-1 andabove, we also assembled a list of NF-B target genes
might continue to proliferate due to repression offrom the published literature that were present on the
p27kip1. Such a B cell might accumulate further onco-Lymphochip microarray (Hinz et al., 2001; Lee et al.,
genic lesions given the fact that the somatic hypermuta-1999; Pahl, 1999) (Figure 4C). It is immediately apparent
tional machinery active in GC B cells introduces double-that GC B cells fail to express most NF-B target genes
stranded DNA breaks (Bross et al., 2000; Papavasiliouincluding many components of the NF-B signaling
and Schatz, 2000).pathway itself (relB, NFB2, and IB). As previously
discussed, many NF-B targets are antiapoptotic (Bcl-2,
Bcl-XL, A1, c-IAP-2), and these are poorly expressed in Gene Expression Profiles and Lymphoid Malignancy
While the immune system is fascinating to observe asGC B cells. Thus, pathway analysis of NF-B target
genes in GC B cells suggests that these cells are poised it functions normally, it is often of greater interest when
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Figure 5. GC B Cells and the Role of BCL-6
(A) Targets of BCL-6 repression (Shaffer et al., 2000) are shown. Samples are the same as in Figure 4A.
(B) BCL-6 target genes and B cell fate decisions. The upper portion of the cartoon represents the possible fate choices for B cells upon
encountering antigen in the periphery. B, B cell; T, T cell; PB, plasmablast; PC, plasma cell; GC, germinal center B cell; and FDC, follicular
dendritic cell. The lower panel shows BCL-6 repressing genes from different signatures, in particular those involved in B cell activation and
terminal differentiation.
things go awry. The most common non-Hodgkin’s lym- tunately fail this treatment. Microarray analysis has been
used to explore the molecular basis for this clinical het-phoma, diffuse large B cell lymphoma (DLBCL), is an
aggressive malignancy of mature B cells that is clinically erogeneity (Alizadeh et al., 2000). Roughly half of the
DLBCL tumor samples studied showed a prominent GCheterogeneous, with40% of patients cured by current
chemotherapy regimens, whereas the remainder unfor- B cell gene expression signature, whereas the other
Immunity
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Jacobs, H. (2000). DNA double-strand breaks in immunoglobulinDLBCL samples instead expressed genes characteristic
genes undergoing somatic hypermutation. Immunity 13, 589–597.of mitogenically activated blood B cells. The GC B cell
Chatterjee-Kishore, M., van den Akker, F., and Stark, G.R. (2000).signature defined a group of patients with good progno-
Association of STATs with relatives and friends. Trends Cell Biol.sis, whereas the activated B cell signature defined a
10, 106–111.
group of patients that were resistant to chemotherapy.
Crabtree, G.R. (1999). Generic signals and specific outcomes: sig-Recent experiments have revealed that the latter group
naling through Ca2, calcineurin, and NF-AT. Cell 96, 611–614.
of patients had tumors that expressed genes in the NF-
de Veer, M.J., Holko, M., Frevel, M., Walker, E., Der, S., Paranjape,
B signature due to constitutive activity of the NF-B
J.M., Silverman, R.H., and Williams, B.R. (2001). Functional classifi-
signaling pathway in these cells (R.E. Davis et al., sub- cation of interferon-stimulated genes identified using microarrays.
mitted). Interference with the NF-B signaling pathway J. Leukoc. Biol. 69, 912–920.
in cell line models of activated B-like DLBCL was lethal, Dent, A.L., Shaffer, A.L., Yu, X., Allman, D., and Staudt, L.M. (1997).
suggesting that this pathway is a new molecular target Control of inflammation, cytokine expression, and germinal center
formation by BCL-6. Science 276, 589–592.for treatment of these often incurable lymphomas (R.E.
Davis et al., submitted). Dimberg, A., Nilsson, K., and Oberg, F. (2000). Phosphorylation-
deficient Stat1 inhibits retinoic acid-induced differentiation and cell
cycle arrest in U-937 monoblasts. Blood 96, 2870–2878.Concluding Remarks
Dustin, M.L., and Cooper, J.A. (2000). The immunological synapseThe concept of a gene expression signature is some-
and the actin cytoskeleton: molecular hardware for T cell signaling.
what fluid and operationally defined. Nonetheless, the Nat. Immunol. 1, 23–29.
success of these signatures in uncovering new biologi-
Eisen, M.B., Spellman, P.T., Brown, P.O., and Botstein, D. (1998).
cal principles is clear. The direct comparison of gene Cluster analysis and display of genome-wide expression patterns.
expression data generated on different experimental Proc. Natl. Acad. Sci. USA 95, 14863–14868.
platforms and in different laboratories may be a chal- Fambrough, D., McClure, K., Kazlauskas, A., and Lander, E.S. (1999).
lenging task. A more easily accomplished goal would Diverse signaling pathways activated by growth factor receptors
induce broadly overlapping, rather than independent, sets of genes.be a gene expression signatures database that would
Cell 97, 727–741.summarize microarray experiments investigating how
Feske, S., Giltnane, J., Dolmetsch, R., Staudt, L.M., and Rao, A.cells differentiate, respond to stimuli, employ transcrip-
(2001). Gene regulation mediated by calcium signals in T lympho-tion factors, and react to drugs. A centralized, publicly
cytes. Nat. Immunol. 2, 316–324.available database of gene expression signatures would
Foletta, V.C., Segal, D.H., and Cohen, D.R. (1998). Transcriptionalmake these signatures useful for the entire immunology
regulation in the immune system: all roads lead to AP-1. J. Leukoc.community and might be a first step toward of genomic
Biol. 63, 139–152.
description of the immune system.
Fukuda, T., Yoshida, T., Okada, S., Hatano, M., Miki, T., Ishibashi,
K., Okabe, S., Koseki, H., Hirosawa, S., Taniguchi, M., et al. (1997).
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